What Happens If You Take the Highest Dose of Wegovy

What the trial data actually shows at the top dose

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and enrolled nearly 2,000 adults with obesity or overweight plus at least one weight-related condition. Participants who reached and stayed on the 2.4mg maintenance dose lost around 15% of their body weight on average. That's a meaningful figure, but it's an average across a wide range of individual responses, and some people lost considerably more while others lost less.

The picture shifted further in early 2026, when the MHRA approved a dedicated 7.2mg single-dose Wegovy pen, making it the highest dose of semaglutide available for weight management in the UK. Trial data for this dose reported average weight loss of around 20.7% over 72 weeks, which narrows the gap considerably with tirzepatide's highest-dose results. For context, that's roughly a fifth of starting body weight. Worth noting: these figures come from participants following structured lifestyle programmes alongside the medicine, so diet and activity remain part of the picture at any dose.

One misconception worth gently setting aside: some people assume that taking more means losing weight faster in proportion. The evidence doesn't quite work that way. Each dose step improves average outcomes, but the increments get smaller as you move up the schedule, and tolerance varies a great deal from person to person. If you're curious about what happens if you take a higher dose of Wegovy, it's worth understanding that the highest dose isn't universally better for everyone, it's optimal for those who respond well and tolerate it.

What your body is likely to experience at 7.2mg or 2.4mg

GLP-1 receptor agonists like semaglutide work partly by slowing how quickly the stomach empties and by signalling fullness to the brain. At higher doses, both of these effects are stronger, which is why greater weight loss is possible, and why the gastrointestinal side-effect profile tends to be more pronounced.

The most commonly reported effects at maintenance doses include nausea, loose stools or constipation, indigestion, burping and fatigue. For most people, these are at their worst during and just after a dose increase, then gradually settle over one to two weeks as the body adjusts. Staying well hydrated, eating smaller portions and avoiding very fatty meals can all help. The NHS medicines page for semaglutide outlines the full side-effect profile with guidance on when to seek medical attention.

Some effects warrant more than patience. Severe, persistent stomach pain that radiates toward the back (with or without vomiting) can be a sign of pancreatitis, which the MHRA highlighted in a January 2026 Drug Safety Update for GLP-1 medicines. Seek urgent medical help if that happens, rather than waiting to see if it settles. Gallbladder symptoms, significant dehydration from repeated vomiting, and signs of an allergic reaction are other reasons to contact a healthcare professional promptly rather than continuing the injection. It's also worth being clear on what happens if you take 2 doses of Wegovy, as doubling up is not safe and should be avoided even if a dose is missed. Suspected side effects can be reported using the MHRA Yellow Card scheme.

How the dose schedule works before you reach the top

No one starts at 2.4mg or 7.2mg. The licensed schedule begins at 0.25mg, progressing through 0.5mg, 1.0mg, 1.7mg and 2.4mg in roughly four-week steps, with the prescriber guiding the pace. The 7.2mg dose is an extension above 2.4mg for those who tolerate and need it, introduced at a subsequent review. That slow climb exists for good reason: it gives the body time to adapt, keeps side effects manageable and means that by the time someone reaches the top dose, they have weeks of accumulated experience with how semaglutide affects them.

Your prescriber can also slow the titration if you're struggling with side effects at any step. A pause at a lower dose is common and does not mean the treatment has failed. The goal is the highest dose you can tolerate well, not the highest dose on the schedule as a fixed target. You can read more about the full Wegovy dosing schedule and what each step involves.

For people already on the 2.4mg injection who are considering the pill form of semaglutide, the situation is different: Wegovy in tablet form has its own licensed dose ladder and transition pathway, assessed separately by a prescriber.

What happens if the highest dose isn't producing results

NICE guidance on semaglutide (TA875) includes a clear stopping rule: if someone hasn't lost at least 5% of their body weight after six months at their highest tolerated maintenance dose, continuing treatment should be clinically reviewed. This isn't a failure, it's a signal that a different approach may suit that person better.

At nume, every repeat order goes through a clinical review before anything is dispensed. That includes checking whether weight loss is progressing in line with what the evidence predicts, whether side effects are manageable, and whether the current dose is still the right one. There's no automatic renewal. The cost of Wegovy treatment and what a full private prescription includes is covered separately if that's useful background. If you'd like to explore whether Wegovy is suitable for you (including whether you might be a candidate for the higher doses) our prescribers can assess that properly. Start your free consultation and a GPhC-registered prescriber will review your details the same day.